The Mumbai-headquartered firm said it has already commenced shipping the product, indicated for use by women to prevent pregnancy, to the US market.
According to IMS MAT Dec 2012 sales data, the total branded and generic sales of the product stood at $161 million.
With the current approval, the company has now received 11 approvals in oral contraceptives (OC) segment in the US market.
The OC market in the US is valued at around $5 billion and growing at around 8% annually.
Shares of Lupin on Friday closed at Rs. 659.65 on the BSE, up 2.29% from their previous close.